Stay updated on Cabozantinib and Nivolumab in Endometrial Cancer Clinical Trial
Sign up to get notified when there's something new on the Cabozantinib and Nivolumab in Endometrial Cancer Clinical Trial page.

Latest updates to the Cabozantinib and Nivolumab in Endometrial Cancer Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoNo Change Detected
- Check18 days agoChange DetectedIntroducing version v3.2.0 and a government-operating-status notice; removing the older v3.1.0 reference.SummaryDifference2%

- Check25 days agoChange Detected- Page now shows that results have been submitted and are available. - Revision updated from v3.0.2 to v3.1.0.SummaryDifference0.1%

- Check39 days agoChange DetectedRevision updated to v3.0.2 and Back to Top removed; no core content or critical information is affected.SummaryDifference0.1%

- Check46 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1.SummaryDifference0.1%

- Check54 days agoChange DetectedThe web page has been updated to include new drug information for Nivolumab and additional resources related to Carcinosarcoma, while removing previous references to Cabozantinib and various location details.SummaryDifference6%

- Check68 days agoChange DetectedThe web page has been updated from version 2.16.11 to version 2.16.12.SummaryDifference0.0%

Stay in the know with updates to Cabozantinib and Nivolumab in Endometrial Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Cabozantinib and Nivolumab in Endometrial Cancer Clinical Trial page.